TLSI

Over the past six months, TriSalus Life Sciences' stock price was significantly impacted by several events. On May 12, 2026, the company reported Q1 results with a 2.92% year-over-year revenue decline and reduced full-year guidance, partly due to lower Q1 revenues from commercial expansion and a delay in FDA clearance for TriNav Advance. This led to a substantial 41.56% stock price drop on May 13, 2026, and the announcement of a securities fraud investigation. On August 6, 2026, Q2 2026 revenues exceeded analyst expectations, but earnings per share lagged. A positive event occurred on September 22, 2026, when the company announced U.S. FDA 510(k) clearance for its TriNav® Advance device, causing its stock price to surge by 29%. The company also participated in various investment conferences, including the H.C. Wainwright & Company 28th Annual Global Investment Conference and the Canaccord Genuity 46th Annual Growth Conference.